Skip to main content
SpringerLink
Log in

Chemoprävention des Prostatakarzinoms

Stand der Dinge

Chemoprevention of prostate cancer

Current status

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Die Chemoprävention hat, nicht zuletzt unter dem Eindruck der Ergebnisse großer prospektiver Studien, in den letzten Jahren zunehmend das Interesse auch der klinisch tätigen Urologen gefunden. In der vorliegenden Bewertung wurde der Begriff „Chemoprävention“ auf alle Substanzen bezogen, die nicht mit der Nahrung aufgenommen wurden. Dabei wurden in erster Linie prospektive Studien berücksichtigt. Die vorliegenden Daten zeigen, dass eine Chemoprävention des Prostatakarzinoms mit dem 5α-Reduktasehemmer Finasterid möglich ist. Daneben existieren jedoch auch Evidenzen für weitere Substanzen aus der Gruppe der selektiven Östrogenrezeptormodulatoren (SERM). Unter Berücksichtigung der Inzidenz sowie der Konsequenzen, die sich für die Betroffenen aus der Diagnose eines Prostatakarzinoms ergeben, hat die wissenschaftliche Auseinandersetzung mit der Chemoprävention des Prostatakarzinoms auch in der Zukunft eine hohe Priorität.

Abstract

Fueled by the results from recently published large interventional trials the topic of chemoprevention of prostate cancer has increasingly attracted the interest of practicing urologists. In this analysis the term“chemoprevention” comprises all agents not included in regular food intake. If possible, the results from interventional studies were considered. Today, it must be accepted as evidence-based that chemoprevention of prostate cancer by 5α-reductase inhibition using finasteride is possible. Furthermore, there is increasing evidence that selective estrogen receptor modulators (SERMs) may also have preventive potential. Prospective interventional trials investigating these substances are currently underway. Considering the high incidence and the fact that the diagnosis of prostate cancer has serious impact on the future life of the respective individuals further scientific evaluation of chemoprevention of prostate cancer is mandatory.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Schmitz-Dräger BJ, Eichholzer M, Beiche B, Ebert T (2001) Nutrition and prostate cancer. Urol Int 67: 1–11

    Article  PubMed  Google Scholar 

  2. Thompson IM, Goodman PJ, Tangen CM et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215–224

    Article  PubMed  Google Scholar 

  3. Scardino P (2003) The prevention of prostate cancer – the dilemma continues. N Engl J Med 349: 297–299

    Article  PubMed  Google Scholar 

  4. Unger JM, LeBlanc M, Thompson IM, Coltman CA Jr (2004) The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies. Urol Oncol 22: 362–368

    PubMed  Google Scholar 

  5. Klein EA, Thompson IM (2004) Update on chemoprevention of prostate cancer. Curr Opin Urol 14: 143–149

    Article  PubMed  Google Scholar 

  6. Ankerst DP, Thompson IM (2006) New answers from the prostate cancer prevention trial on the chemoprevention of prostate cancer. Arch Ital Urol Androl 78: 154–156

    PubMed  Google Scholar 

  7. Teillac P, Abrahamsson PA (2006) The prostate cancer prevention trial and its implications for clinical practise: a European consensus. Eur Urol 5(Suppl): 640–646

    Article  Google Scholar 

  8. Stellungnahme des Arbeitskreises Prävention, Umwelt und Komplementärmedizin (PUK) und des Arbeitskreises Onkologie (AKO) der Akademie der Deutschen Urologen (2006) Chemoprävention des Prostatakarzinoms – eine Neubewertung. Blickpunkt DER MANN 4: 47

    Google Scholar 

  9. Andriole G, Bostwick D, Brawley O et al. (2004) Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 172: 1314–1317

    Article  PubMed  Google Scholar 

  10. Roberts EG, Vona-Davis L, Riggs DR et al. (2004) COX-2 inhibition and cancer: experimental findings and clinical correlates. W V Med J 100: 96–110

    PubMed  Google Scholar 

  11. Beauchamp GK, Keast RS, Morel D et al. (2005) Phytochemistry: ibuprofen-like activity in extra-virgin olive oil. Nature 437: 45–46

    Article  PubMed  Google Scholar 

  12. Mahmud S, Franco E, Aprikian A (2004) Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 90: 93–99

    Article  PubMed  Google Scholar 

  13. Thomas LG (2005) Increased risk of cardiovascular events with coxibs and NSAIDs. Lancet 365: 1538–1539

    Article  Google Scholar 

  14. Price D, Stein B, Goluboff E et al. (2006) Toremifene for the prevention of prostate cancer among 514 men with high-grade prostatic intraepithelial neoplasia (PIN): results of a double-blind, placebo-controlled phase IIB trial. J Urol 176: 965–970

    Article  Google Scholar 

  15. Malik A, Afaq F, Sarfaraz S et al. (2005) Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci USA 102: 14813–14818

    Article  PubMed  Google Scholar 

  16. Moyad MA (2004) Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I. Urol Oncol 22: 466–471

    PubMed  Google Scholar 

  17. Moyad MA (2004) Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II. Urol Oncol 22: 472–477

    PubMed  Google Scholar 

  18. Strom SS, Wang X, Pettaway CA et al. (2005) Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11: 6889–6894

    Article  PubMed  Google Scholar 

  19. Hsieh LJ, Carter HB, Landis PK et al. (2003) Association of energy intake with prostate cancer in a long-term aging study: Baltimore Longitudinal Study of Aging (United States). Urology 61: 297–301

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Urologie, EuromedClinic, Europa-Allee 1, 90763, Fürth, Deutschland

    B.J. Schmitz-Dräger

  2. Urologische Klinik, St. Josef-Hospital, Troisdorf, Deutschland

    G. Lümmen

  3. Urologie am Theaterplatz, Bad Godesberg, Deutschland

    R.M. Schäfer

Authors
  1. B.J. Schmitz-Dräger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Lümmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R.M. Schäfer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B.J. Schmitz-Dräger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmitz-Dräger, B., Lümmen, G. & Schäfer, R. Chemoprävention des Prostatakarzinoms. Urologe 46, 611–615 (2007). https://doi.org/10.1007/s00120-007-1352-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-007-1352-3

Schlüsselwörter

Keywords

Search

Navigation